Background: The goal of intestinal rehabilitation in children is to wean from parenteral nutrition (PN). The aim of this study was to identify factors associated with accelerated weaning and to evaluate long-term outcomes of children receiving long-term PN.
Methods: This was a retrospective study of children managed by the Intestinal Rehabilitation Center at Cincinnati Children's Hospital.
Setting: The burden of congenital anomalies is a significant public health concern. In response to the World Health Organization's recommendations, Canada developed and strengthened congenital anomalies surveillance to build capacity for prevention and optimal health outcomes. Historically, the Public Health Agency of Canada (PHAC) exclusively used hospital discharge data for the Canadian Congenital Anomalies Surveillance System (CCASS).
View Article and Find Full Text PDFElotuzumab is an approved monoclonal antibody targeting SLAMF7 on plasma and NK cells that enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory MM. We therefore studied adding elotuzumab to PVd (elo-PVd) in relapsed/refractory MM in a multicenter phase 2 trial.
View Article and Find Full Text PDFAim Of The Study: This study examines the extent to which a structured implementation of guidelines for the prevention of coercion leads to an improvement in guideline-compliant work and the reduction of coercion in routine clinical practice.
Methods: This is a secondary analysis of the shift of outcomes in the PreVCo study, which was conducted on 55 psychiatric wards throughout Germany.
Results: The number of coercive measures decreased significantly during the observation period.